CSL Receives Health Canada Approval for Andembry

CSL, a healthcare company, has obtained approval from Health Canada for its treatment Andembry, which is intended to address hereditary angioedema.

Key Details

• Date of approval: Not specified
• Treatment: Andembry
• Indication: Hereditary angioedema
• Regulatory body: Health Canada

CSL Stock Performance

CSL’s share price has fluctuated in recent periods, reaching a 52-week high of 311.38 AUD and a low of 228.61 AUD.

Financial Ratios

• Price-to-earnings ratio: 31.25
• Price-to-book ratio: 4.61